NCT04384653View on ClinicalTrials.gov

Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 17, 2020

Primary Completion Date

June 12, 2021

Study Completion Date

June 12, 2021

Conditions
Heart Failure
Interventions
DRUG

Furosemide Injection Solution for subcutaneous administration (80 mg)

Furosemide Injection Solution for subcutaneous administration (80 mg)

DRUG

Furosemide Injection, USP

Furosemide Injection, USP (10 mg/mL), 80 mg by intravenous administration

DEVICE

Medfusion 3500 (v6) precision infusion pump

Furosemide Injection Solution for subcutaneous administration (80 mg)

Trial Locations (1)

32720

Accel Research Sites - DeLand Clinical Research Unit, DeLand

Sponsors

Collaborators (1)

Accel Clinical Services
All Listed Sponsors
collaborator

Accel Clinical Services

INDUSTRY

lead

SQ Innovation, Inc.

INDUSTRY

NCT04384653 - Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure | Biotech Hunter | Biotech Hunter